Use of Cinnamomum Verum for Induction of Labor. Double Blind Randomized Clinical Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cinnamomum Verum oil extract, Placebo.
- Who it may be relevant to
- Registry conditions: Labor Onset and Length Abnormalities, First Birth. Basic parameters: 14 years — 45 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Honduras
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Use of Cinnamomum Verum Extract Versus Placebo for Induction of Labor and Reduction of Physiological Phase 2-3 of Labor. Double-blind Randomized Clinical Trial. CINNALAB TRIAL
Overview
The purpose of the research protocol is to evaluate the effectiveness of Cinnamomum verum extract for the initiation of labor. Cinnamaldehyde ((E)-3-Phenylprop-2-enal) is an α, β unsaturated aromatic aldehyde, derived from cinnamon (Cinnamomum Verum oil) used as a flavoring; It is a clear yellowish liquid substance, with a strong odor and flavor. It is the main component of cinnamon (63%), giving it its physicochemical properties. Cinnamon has been an element of empirical use for the beginning of labor, however, its effectiveness has not been demonstrated. Cinnamon has been reported for its ethnopharmacological properties in pregnancy, being used to facilitate childbirth, as a lactagogue and for postpartum recovery. In Honduras, its use has been reported to relieve nausea and vomiting during pregnancy, to reduce abdominal pain. , reduction of lower limb edema, to relieve anxiety during labor, as well as a lactagogue without convergent opinions.
Detailed description
clinical trial of parallel groups of effectiveness, 2 groups will be taken, the intervention group will be administered capsules of Cinnamomum verum concentrate (1000 mg orally per day, a single dose) containing 67% cinnamaldehyde, one capsule per day will be administered (oral dose cinnamaldehyde lethal dose (LD50) of 1.15 g/kg), each capsule contains 1000 mg of Cinnamomum verum bark concentrate in soft gelatin capsules which are odorless and tasteless.
The control group will be administered canola oil capsules, a dose of 400 mg orally per day, a single dose per day. These soft gelatin capsules are odorless and tasteless.
Both capsules have identical physical characteristics. (they are soft gelatin capsules with the same color and smell)
Interventions
- Drug Cinnamomum Verum oil extract
one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days - Drug Placebo
400 mg PO Canola oil soft gel capsule
Primary outcome measures
- Onset of labor [Time frame: 21-28 days]
Secondary outcome measures (4)
- duration on labor [Time frame: 24 hours]
- cesarean section and/or instrumental delivery [Time frame: 1-2 hours]
- Neonatal complications [Time frame: 28 days]
- macrosomia [Time frame: 1 hour]
Eligibility criteria
Inclusion criteria
- Delivery of an informed consent form signed and dated by parents or guardian and patient
- Declared willingness to comply with all study procedures and availability for the duration of the study.
- provision of appropriate consent and assent
- Willingness and ability to participate in study procedures
- Patients under 18 years of age
- Full-term pregnancies (37-41 Weeks of Gestation).
- Nulliparity
- Have your own cell phone
- Know how to read and write
- Residing in Tegucigalpa
- Be in good general health, as evidenced by your medical history
- Ultrasound with amniotic fluid index > 5 cm
- Non Stress Test Reactive
- Ability to take oral medication and be willing to comply with the cinnamon capsule regimen
Exclusion criteria
- Current use of antihypertensive or hypoglycemic medications
- Presence of non-curable chronic diseases prior to pregnancy or during pregnancy such as hypertension, diabetes, hypothyroidism
- Premature rupture of membranes
- Infections (urinary tract infection, chorioamnionitis) present at the time of the study (diagnosed with symptoms or leukocytes >12,500 or pathological urine examination)
- Allergies to cinnamaldehyde or cinnamon, canola oil
- Multiple pregnancy
- Major fetal malformations
- Fetal death
- Non-cephalic presentation
- Severe oligohydramnios (amniotic fluid index < 2 cm)
- Having consumed or being consuming cinnamon products 7 days before the start of the study
- Febrile illness within 7 days before starting to take cinnamon
- Treatment with another investigational drug or other intervention within 7 days prior to the start of the intervention
- Current smoker or tobacco use
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Other
Study locations
Honduras · 1 center
- Hospital Escuela — Tegucigalpa
Identifiers
NCT: NCT06164613 · CV-LT-01-2023